Delivery Order SPE2DB25D3008-SPE2DB25FRCTA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package. This order is valued at $1,825.56 with a firm fixed price structure and carries a completion date of July 30, 2025. The contract involves no set-aside designation, indicating it was competitively awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,358.11 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 25, 2025. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $6,100.21 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The order was placed to the company's place of performance in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets, with a ceiling value of $67,208.92. This non-set-aside, competitively awarded contract employs firm fixed pricing and maintains an ultimate completion date of August 18, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,756.44. This competitively awarded, firm fixed-price delivery order is not associated with any set-aside program and is scheduled for ultimate completion by August 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,971.96. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The order is scheduled for ultimate completion on August 27, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $1,250.64. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $4,022.60. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is expected to reach completion by September 9, 2025. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRCTADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $8,612.00. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. That prime contract vehicle provides comprehensive global pharmaceutical support, enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. The current delivery order for Dapagliflozin, a diabetes medication, exemplifies the company's role in fulfilling critical pharmaceutical requirements for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 7/25/25 |